Fund Insights
Common Fund Bets
See what stocks and ETFs funds are collectively bullish/bearish on
Largest Fund Trades
Explore the largest stock and ETF buys and sells made by funds
Fund Manager Portfolios
Gain insights from the world's largest funds and super investors
Analyst Insights
Price Target Consensus
See what stocks research analysts are collectively bullish/bearish on
Latest Ratings Feed
Explore the latest ratings and price targets from the best equity research analysts
Equity Analyst Profiles
Browse analysts, their latest ratings and track record
Research Firm Profiles
Browse research firm recommendations, trends, and performance
WSR Indexes
Fund Manager Index
Stock index based on fund manager consensus updated each quarter
Analyst Index
COMING SOON - Stock index based on equity analyst consensus updated every second
Search
Sign in
Sign up
CareDx
CDNA
Market cap
$764M
Overview
Fund Trends
Analyst Outlook
Journalist POV
14.70
USD
+0.35
2.44%
At close
Updated
Oct 15, 4:00 PM EDT
Pre-market
After hours
14.70
0.00
0%
1D
5D
1M
3M
6M
YTD
1Y
5Y
10Y
1 day
2.44%
5 days
-0.47%
1 month
4.85%
3 months
-22.67%
6 months
-23.28%
Year to date
-31.69%
1 year
-44.21%
5 years
-71.85%
10 years
223.79%
Positive
Neutral
Negative
Sentiment
3-Months
Positive
Neutral
66.7%
Negative
Positive
Neutral
Negative
Neutral
Business Wire
10 days ago
CareDx Announces New IVD Products and IVDR Certification for AlloSeq® Tx and QTYPE® at the 2025 American Society of Histocompatibility & Immunogenetics Annual Meeting
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced new innovations and products that will be featured at The American Society for Histocompatibility and Immunogenetics (ASHI) 2025 Annual Meeting, held October 6th to 10th in Orlando.
Neutral
Business Wire
1 month ago
CareDx Issues Comment Letter on Draft LCD Policy
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that it has submitted its comment letter in response to the draft Local Coverage Determination (LCD) related to molecular testing for solid organ transplant rejection. The comment letter has.
Negative
Benzinga
1 month ago
CareDx Battles Reimbursement Uncertainty As Market Overlooks Long-Term Potential
CareDx, Inc. CDNA faces fresh uncertainty as proposed reimbursement changes threaten its core testing business, clouding near-term growth even as the company's expanding transplant solutions platform positions it for long-term opportunity in an $8 billion market.
Neutral
Business Wire
1 month ago
CareDx to Participate in Wells Fargo Healthcare Conference
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced the company will participate in a fireside chat at the Wells Fargo Healthcare Conference in Boston, Massachusetts, on September 5, 2025, at 8:00 AM ET. A live and archived webcast of the pres.
Positive
The Motley Fool
2 months ago
CareDx (CDNA) EPS Beats Sales Gain 14%
CareDx (CDNA) EPS Beats Sales Gain 14%
Neutral
Seeking Alpha
2 months ago
CareDx, Inc (CDNA) Q2 2025 Earnings Call Transcript
CareDx, Inc (NASDAQ:CDNA ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Abhishek Jain - CFO & Principal Accounting Officer Caroline Corner - Corporate Participant John Walter Hanna - President, CEO & Director Keith S. Kennedy - Chief Operating Officer Conference Call Participants Brandon Couillard - Wells Fargo Securities, LLC, Research Division Mark Anthony Massaro - BTIG, LLC, Research Division Tycho W.
Positive
Zacks Investment Research
2 months ago
Here's What Key Metrics Tell Us About CareDx (CDNA) Q2 Earnings
The headline numbers for CareDx (CDNA) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Negative
Zacks Investment Research
2 months ago
CareDx (CDNA) Lags Q2 Earnings and Revenue Estimates
CareDx (CDNA) came out with quarterly earnings of $0.1 per share, missing the Zacks Consensus Estimate of $0.12 per share. This compares to earnings of $0.25 per share a year ago.
Neutral
Business Wire
2 months ago
CareDx Announces Appointment of Nathan Smith as Chief Financial Officer
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the appointment of Nathan Smith to the role of Chief Financial Officer. Nathan will lead key financial and accounting initiatives that are a part of the Company's long-term strategic growth p.
Neutral
Business Wire
2 months ago
CareDx Announces Second Quarter 2025 Financial Results
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company - a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today reported financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Highlights Reported revenue of $86.7 million including a $3.8 million write-off of aged receivables ass.
Show more
See News Rankings
Sign up
Sign in
Fund Insights
Common Fund Bets
See what stocks and ETFs funds are collectively bullish/bearish on
Largest Fund Trades
Explore the largest stock and ETF buys and sells made by funds
Fund Manager Portfolios
Gain insights from the world's largest funds and super investors
Analyst Insights
Price Target Consensus
See what stocks research analysts are collectively bullish/bearish on
Latest Ratings Feed
Explore the latest ratings and price targets from the best equity research analysts
Equity Analyst Profiles
Browse analysts, their latest ratings and track record
Research Firm Profiles
Browse research firm recommendations, trends, and performance
WSR Indexes
Fund Manager Index
Stock index based on fund manager consensus updated each quarter
Analyst Index
COMING SOON - Stock index based on equity analyst consensus updated every second
Theme
Close